Workflow
KalVista Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Group 1 - KalVista Pharmaceuticals is set to release its first-quarter earnings results on September 11, with analysts expecting a loss of $0.96 per share compared to a loss of $0.87 per share in the same quarter last year [1] - The company is projected to report quarterly revenue of $2.09 million [1] - On August 11, KalVista announced the maintenance of Orphan Designation for Sebetralstat in the European Union [2] Group 2 - KalVista Pharmaceuticals shares experienced a decline of 2.2%, closing at $15.61 [2] - Analysts have provided various ratings for KalVista, with HC Wainright & Co. maintaining a Buy rating and a price target of $27 [4] - JMP Securities increased its price target for KalVista from $19 to $27 while maintaining a Market Outperform rating [4]